



NZX/ASX Announcement

15 June 2026

Rights Issue Closing

TruScreen Group Limited (NZX/ASX:TRU) (TruScreen or the Company), a global leader in AI-enabled cervical cancer screening, wish to advise that the closing date for the Renounceable Rights issue is 5pm NZT (3pm AEST) on Wednesday 17 June 2025.

The rights issue price is NZ\$0.013 (A\$0.011) per new share.

If you are not in a position to apply online or have any questions about the process for participating in the Rights Offer, please contact MUFG Pension & Market Services at your earliest convenience on +64 9 375 5998 between 8.30am to 5pm (NZT) Monday to Friday to discuss alternative options or email applications.nz@cm.mpms.mufg.com. Please use "TruScreen Rights Offer" as the subject line of the email.

Ends

For more information, visit www.truscreen.com or contact:

Tony Ho
Non-Executive Chairman
tonyho@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Omar Taheri
Media & Investor Relations
omar@sparkplus.org



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day.

To learn more, please visit: www.daltonbio.com/.